SCHEMBL6528085

SCHEMBL6528085

COc1ccc(OCc2ccccc2)c(-c2ccnn2-c2ccccn2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 5/20 0.48
PTGER1 P34995 1/20 0.47
HTT P42858 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
KDM5A P29375 2/20 0.43
KDM4C Q9H3R0 2/20 0.43
KDM5B Q9UGL1 2/20 0.43
MAOB P27338 1/20 0.41
SGMS2 Q8NHU3 1/20 0.41
LRRK2 Q5S007 1/20 0.40
SLC16A3 O15427 1/20 0.40
AURKB Q96GD4 1/20 0.40
INCENP Q9NQS7 1/20 0.40
ABCB1 P08183 1/20 0.40
HTR1A P08908 1/20 0.40
DRD2 P14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6451994 0.81 PTGER1 (0.42) SYKPTGER1TSHRMAOBSGMS2
SCHEMBL6448858 0.81 SYK (0.55) SYKPTGER1HTTKDM4EALDH1A1
SCHEMBL6530306 0.80 SYK (0.47) SYKHTTKDM4EALDH1A1LMNA
SCHEMBL6450170 0.79 MAPT (0.48) HTTKDM4EALDH1A1LMNAMAPK1
SCHEMBL6454400 0.77 KDM4A (0.46) SYKKDM4EALDH1A1LMNAKDM5A
SCHEMBL3362290 0.75 GRM4 (0.55) HTTKDM4EALDH1A1LMNATSHR
SCHEMBL6450478 0.73 PDCD1 (0.49) KDM4EALDH1A1TSHRKDM5AKDM4C
SCHEMBL15778047 0.73 KDM5A (0.64) HTTKDM5AKDM4CKDM5BNPC1
SCHEMBL6454291 0.73 HTT (0.42) SYKHTTSGMS2MAPT
SCHEMBL6449630 0.72 SYK (0.54) SYKPTGER1HTTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus ANADYS PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus HAVCR2, HCCS, LIPC SYK 4094/4885PTGER1 3096/4885HTT 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.